Loading organizations...
Loading organizations...
100x faster scientific evidence synthesis
Key people at The Synthesis Company.
The Synthesis Company was founded in 2024 by Amir Mehr (Co-Founder) and Cyrus Nouroozi (Co-Founder).
We enable research that was previously impossible:systematic reviews of 20,000+ papers in weeks with 98% accuracy.
We collaborate with researchers at Stanford, Harvard, and Johns Hopkins to ask the big questions they've been forced to scale down.
Pharma companies get complete evidence awareness in weeks : not years.
AI labs get the same reviews as RL environments with expert-validated reasoning traces:scientific synthesis as the next frontier after math and coding benchmarks.
We're former DSPy core contributors who built the production infrastructure to make total evidence awareness actually work at scale.
The Synthesis Company was founded in 2024 by Amir Mehr (Co-Founder) and Cyrus Nouroozi (Co-Founder).
The Synthesis Company builds advanced AI-powered tools that enable scientific evidence synthesis up to 100x faster than traditional methods. Their platform automates the aggregation, analysis, and summarization of vast scientific literature, primarily serving biopharma companies, researchers, and regulatory bodies. By drastically reducing the time and cost of evidence synthesis, they solve the critical problem of slow, labor-intensive literature reviews that delay drug development, regulatory submissions, and market access decisions. This acceleration supports faster innovation cycles and more informed decision-making in life sciences, positioning the company as a key enabler in the scientific research ecosystem.
For an investment firm, The Synthesis Company represents a high-impact portfolio company focused on transforming scientific research workflows through AI, targeting the growing demand for rapid, reliable evidence synthesis in healthcare and biopharma sectors. Their technology enhances the startup ecosystem by enabling faster validation of scientific hypotheses and accelerating product development timelines.
The Synthesis Company was founded by experts with deep backgrounds in AI, data science, and life sciences, motivated by the inefficiencies in traditional evidence synthesis processes that often take 12-18 months to complete. The idea emerged from recognizing the bottleneck in clinical research and regulatory workflows caused by manual literature reviews and meta-analyses. Early traction came from partnerships with biopharma firms needing faster regulatory submissions and market access strategies, validating the platform’s ability to deliver comprehensive, high-quality evidence synthesis at unprecedented speed.
The Synthesis Company rides the wave of AI-driven transformation in scientific research and healthcare decision-making. The timing is critical as the volume of scientific publications grows exponentially, making manual synthesis impractical. Market forces such as increasing regulatory complexity, demand for faster drug approvals, and the push for evidence-based policy amplify the need for scalable synthesis solutions. By enabling living evidence syntheses—continuously updated reviews—they influence the broader ecosystem by promoting open science, transparency, and faster translation of research into practice.
Looking ahead, The Synthesis Company is poised to expand its impact by integrating more advanced AI capabilities like natural language understanding and predictive analytics to further enhance evidence synthesis quality and speed. Trends such as personalized medicine, real-world evidence integration, and global health equity will shape their journey, potentially broadening their platform beyond biopharma into other scientific domains. Their influence will likely grow as they become a foundational infrastructure for scientific knowledge aggregation, accelerating innovation and evidence-based decision-making worldwide.
Key people at The Synthesis Company.
